Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

Ardelyx (ARDX) reported $74.11 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 61.1%. EPS of -$0.17 for the same period compares to -$0.11 a year ago.

The reported revenue represents a surprise of -8.14% over the Zacks Consensus Estimate of $80.68 million. With the consensus EPS estimate being -$0.10, the EPS surprise was -70.00%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Ardelyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product sales, net: $67.81 million versus the six-analyst average estimate of $77.61 million. The reported number represents a year-over-year change of +55.9%.
• Product sales- IBSRELA: $44.40 million compared to the $53.71 million average estimate based on six analysts.
• Product sales- XPHOZAH: $23.41 million versus $24.55 million estimated by six analysts on average.
• Revenues- Product supply: $0.25 million versus the four-analyst average estimate of $3.70 million. The reported number represents a year-over-year change of -88.1%.
• Non-cash royalty revenue related to the sale of future royalties: $1.03 million compared to the $0.68 million average estimate based on two analysts.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research